scholarly journals Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper

2019 ◽  
Vol 10 (3) ◽  
pp. 389-397 ◽  
Author(s):  
Esther Bastiaannet ◽  
Nicolò Battisti ◽  
Kah Poh Loh ◽  
Nienke de Glas ◽  
Enrique Soto-Perez-de-Celis ◽  
...  
Keyword(s):  
International Society ◽  
Targeted Therapies ◽  
Older Patients ◽  
Review Paper ◽  
Geriatric Oncology ◽  
Advanced Melanoma ◽  
Oncology Review

scholarly journals Falls in older patients with cancer: Nursing and Allied Health Group of International Society of Geriatric Oncology review paper

2020 ◽  
Vol 11 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Schroder Sattar ◽  
Cindy Kenis ◽  
Kristen Haase ◽  
Peggy Burhenn ◽  
Petra Stolz-Baskett ◽  
...  
Keyword(s):  
International Society ◽  
Older Patients ◽  
Allied Health ◽  
Review Paper ◽  
Geriatric Oncology ◽  
Patients With Cancer ◽  
Cancer Nursing ◽  
Health Group ◽  
Oncology Review

Systemic Therapy of Common Tumours in Older Patients: Challenges and Opportunities. A Young International Society of Geriatric Oncology Review Paper

2020 ◽  
Vol 22 (10) ◽  
Author(s):  
Nicolò Matteo Luca Battisti ◽  
Gabor Liposits ◽  
Nienke Aafke De Glas ◽  
Fabio Gomes ◽  
Capucine Baldini ◽  
...  
Keyword(s):  
International Society ◽  
Systemic Therapy ◽  
Older Patients ◽  
Review Paper ◽  
Geriatric Oncology ◽  
Oncology Review ◽  
Challenges And Opportunities

PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper

2019 ◽  
Vol 10 (2) ◽  
pp. 337-345 ◽  
Author(s):  
Gabor Liposits ◽  
Kah Poh Loh ◽  
Enrique Soto-Perez-de-Celis ◽  
Lucy Dumas ◽  
Nicolò Matteo Luca Battisti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
International Society ◽  
Older Patients ◽  
Review Paper ◽  
Geriatric Oncology ◽  
Parp Inhibitors ◽  
Oncology Review

scholarly journals Social support for older adults with cancer: Young International Society of Geriatric Oncology review paper

2020 ◽  
Vol 11 (2) ◽  
pp. 217-224 ◽  
Author(s):  
Sindhuja Kadambi ◽  
Enrique Soto-Perez-de-Celis ◽  
Tullika Garg ◽  
Kah Poh Loh ◽  
Jessica L. Krok-Schoen ◽  
...  
Keyword(s):  
Social Support ◽  
Older Adults ◽  
International Society ◽  
Review Paper ◽  
Geriatric Oncology ◽  
Oncology Review

scholarly journals Arti Hurria and the progress in integrating the geriatric assessment into oncology: Young International Society of Geriatric Oncology review paper

2020 ◽  
Vol 11 (2) ◽  
pp. 203-211 ◽  
Author(s):  
Clark DuMontier ◽  
Mina S. Sedrak ◽  
Wee Kheng Soo ◽  
Cindy Kenis ◽  
Grant R. Williams ◽  
...  
Keyword(s):  
Geriatric Assessment ◽  
International Society ◽  
Review Paper ◽  
Geriatric Oncology ◽  
Oncology Review

scholarly journals Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper

2018 ◽  
Vol 10 ◽  
pp. 175883591880961 ◽  
Author(s):  
Nicolò Matteo Luca Battisti ◽  
Nienke De Glas ◽  
Mina S. Sedrak ◽  
Kah Poh Loh ◽  
Gabor Liposits ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Older Adults ◽  
Older Patients ◽  
Geriatric Oncology ◽  
Growth Factor Receptor ◽  
Standard Of Care ◽  
Cyclin Dependent Kinase ◽  
Current Standard ◽  
Oncology Review ◽  
Er Positive

The current standard of care for the management of estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer has been redefined by the introduction of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Although adults aged 65 years and older account for the majority of patients with breast cancer, limited data are available about the age-specific dosing, tolerability, and benefit of CDK4/6 inhibitors in this growing population. Older adults are under-represented in clinical trials and as a result, clinicians are forced to extrapolate from findings in younger and healthier patients when making treatment decisions for older patients. In this article, we review the limited age-specific evidence on the efficacy, toxicity, and quality of life (QoL) outcomes associated with the use of CDK4/6 inhibitors in older adults. We also describe ongoing trials evaluating CDK4/6 inhibitors in the older population and highlight that only a minority of adjuvant and metastatic trials of CDK4/6 inhibitors in the general breast cancer population includes geriatric assessments. Finally, we propose potential strategies to help guide decision making for fit and unfit older patients based on disease endocrine sensitivity, the need for rapid response and geriatric assessment.

scholarly journals Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013

2015 ◽  
Vol 26 (3) ◽  
pp. 463-476 ◽  
Author(s):  
D. Papamichael ◽  
R.A. Audisio ◽  
B. Glimelius ◽  
A. de Gramont ◽  
R. Glynne-Jones ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
International Society ◽  
Older Patients ◽  
Geriatric Oncology ◽  
Consensus Recommendations
Sign in / Sign up

Export Citation Format

Share Document